Abstract
Adrenomedullin (AM) is a vascular–derived polypeptide that exerts numerous actions in cardiovascular homeostasis. Recent studies have demonstrated a cytoprotective action of exogenously applied or genetically over–expressed AM in experimental myocardial infarction. The present studies were undertaken to test the hypothesis that AM exerts its effects through direct augmentation of NO generation in the myocardium during early reperfusion. Rat isolated hearts underwent 35 min left coronary artery occlusion followed by 120 min reperfusion. Infarct size (as percentage of ischaemic riskzone) was determined by Evans’ blue and tetrazolium double staining. AM 1 nM administered 5 min prior to and during the first 15 min of ischaemia did not significantly influence infarct size. However, the same concentration of AM given during the last 5 min ischaemia and first 15 min of reperfusion significantly limited infarct size (AM reperfusion 15.9 ± 3.5% vs control 31.4 ± 2.1%, P < 0.01). AM at reperfusion improved coronary flow and LV contractility. The protective effects of adrenomedullin were abolished in the presence of the NO synthase inhibitor, L–NAME 100 µM (infarct size 24.6 ± 5.7%, P > 0.05 vs control). AM treatment at reperfusion was associated with augmented phosphorylation of the pro–survival kinase, Akt, determined by immunoblotting of tissue sampled 30 min following reperfusion. These studies provide the first evidence that AM exerts its cytoprotective action specifically during early reperfusion through a NO–dependent mechanism.
Similar content being viewed by others
Abbreviations
- AM:
-
= adrenomedullin
- CFR:
-
= coronary flow rate
- L–NAME:
-
= Nω–nitro–L–arginine methyl ester
- NO:
-
= nitric oxide
- NOS:
-
= nitric oxide synthase
References
Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM (2001) Cardioprotective effects of transforming growth factor–beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 38:930–939
Baxter GF, Yellon DM (2003) Current trends and controversies in ischemiareperfusion research – meeting report of the Hatter Institute 3rd International Workshop on Cardioprotection. Basic Res Cardiol 98:133–136
Bell RM, Yellon DM (2003) Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35:185–193
D’Souza SP, Yellon DM, Martin C, Schulz R, Heusch G, Onody A, Ferdinandy P, Baxter GF (2003) B–type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physio 284:H1592–H1600
Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P (2001) Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial andcytosolic NAD+ and is a causative eventin the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276:2571–2575
Ferdinandy P, Schulz R (2003) Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia–reperfusion injury and preconditioning. Br J Pharmacol 138:532–543
Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC (1999) Regulation of endothelium–derived nitric oxide production by the protein kinase Akt. Nature 399:597–601
Hamid SA, Baxter GF (2005) Adrenomedullin: regulator of systemic and cardiac homeostasis in acute myocardial infarction. Pharmacol Ther 105:95–112
Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM (2002) Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55:534–543
Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia–reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)–pathway. Cardiovasc Res 61:448–460
Hayakawa H, Hirata Y, Kakoki M, Suzuki Y, Nishimatsu H, Nagata D, Suzuki E, Kikuchi K, Nagano T, Kangawa K, Matsuo H, Sugimoto T, Omata M (1999) Role of nitric oxide–cGMP pathway in adrenomedullin–induced vasodilation in the rat. Hypertension 33:689–693
Kato J, Kitamura K, Kangawa K, Eto T(1995) Receptors for adrenomedullin in human vascular endothelial cells. Eur J Pharmacol 289:383–385
Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J (2003) Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol 285:H1506–H1514
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T(1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys ResCommun 192:553–560
Kobara M, Tasumi T, Takeda M, Mano A, Yamanaka S, Shirasihi J, Keira N, Matoba S, Asayama J, Nakagwa M (2003) The dual effects of nitric oxide synthase inhibitorson ischemia–reperfusion injury in rat hearts. Basic Res Cardiol 98:319–328
Kobayashi K, Kitamura K, Hirayama N, Date H, Kashiwagi T, Ikushima I, Hanada Y, Nagatomo Y, Takenaga M, Ishikawa T, Imamura T, Koiwaya Y, Eto T (1996)Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 131:676–680
Kureishi Y, Kobayashi S, Nishimura J, Nakano T, Kanaide H (1995) Adrenomedullin decreases both cytosolic Ca2+ concentration and Ca(2+)–sensitivity in pig coronary arterial smooth muscle. Biochem Biophys Res Commun 212:572–579
Nagaya N, Nishikimi T, Yoshihara F, Horio T, Morimoto A, Kangawa K (2000) Cardiac adrenomedullin gene expression and peptide accumulation after acute myocardial infarction in rats. Am J Physiol Regul Integr Comp Physiol 278:R1019–R1026
Nakamura R, Kato J, Kitamura K, Onitsuka H, Imamura T, Cao Y, Marutsuka K, Asada Y, Kangawa K, Eto T(2004) Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation. Jul 27 110 (4):426–431
Oie E, Vinge LE, Yndestad A, Sandberg C, Grogaard HK, Attramadal H (2000) Induction of a myocardial adrenomedullin signaling system during ischemic heart failure in rats. Circulation 101:415–422
Okumura H, Nagaya N, Itoh T, Okano I, Hino J, Mori K, Tsukamoto Y, Ishibashi–Ueda H, Miwa S, Tambara K, Toyokuni S, Yutani C, Kangawa K (2004)Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3–kinase/Akt–dependent pathway. Circulation 109:242–248
Piper HM, Abdallah Y, Schafer C (2004) The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61:365–371
Schafer A, Burkhardt M, Vollkommer T, Bauersachs J, Munzel T, Walter U, Smolenski A (2003) Endotheliumdependent and –independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide–elevating vasodilators in rat aorta. Biochem Pharmacol 65:397–405
Schulz R, Kelm M, Heusch G (2004) Nitricoxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 61:402–413
Stangl K, Dschietzig T, Richter C, Stangl V, Bartsch C, Zurbrugg HR, Pregla R, Baumann G, Felix SB, Laule M (2002) Cessation of pulmonary and coronary secretion of adrenomedullin peptides in the progression of human heart failure. Horm Metab Res 34:81–86
Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H (1994)Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor–alpha. Biochem Biophys Res Commun 203:719–726
Yang XM, Krieg T, Cui L, Downey JM, Cohen MV (2004) NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36:411–421
Yellon DM, Baxter GF (1999) Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 9:245–249
Yin H, Chao L, Chao J (2004) Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt–GSK signaling. Hypertension 43:109–116
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hamid, S.A., Baxter, G.F. Adrenomedullin limits reperfusion injury in experimental myocardial infarction. Basic Res Cardiol 100, 387–396 (2005). https://doi.org/10.1007/s00395-005-0538-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00395-005-0538-3